Breast Cancer Risk Factors According to Joint Estrogen Receptor and Progesterone Receptor Status
Overview
Affiliations
Background: We investigated risk factor patterns for subtypes of breast cancer characterized by joint estrogen receptor (ER) and progesterone receptor (PR) status in a hospital-based case-control study.
Methods: ER and PR tumor status were determined immunohisotchemically. Risk factors of interest were entered into a multiple polychotomous logistic regression model simultaneously; odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. Using this model, cases in the four tumor subtypes (ER+PR+, ER-PR-, ER+PR-, ER-PR+) were compared simultaneously to controls. A Wald test for heterogeneity across the four subtypes was conducted, as well as a case-case comparison between the two most biologically disparate subtypes, ER+PR+ and ER-PR-.
Results: The receptor status distribution was as follows: 33% ER+PR+, 34% ER-PR-, 20% ER+PR-, and 13% ER-PR+. Among 317 cases and 401 controls, we found significant heterogeneity across the four tumor subtypes for older age at first full-term pregnancy (p=0.04) and post-menopausal status (p=0.04). For older age at first full-term pregnancy, an elevated risk was found for the ER+PR- subtype (OR=2.5; 95% CI: 1.2-5.1). For post-menopausal status, elevated risks were found for both the ER+PR+ (OR=2.4; 95% CI: 1.1-4.9) and ER+PR- (OR=7.2; 95% CI: 2.4-21.7) subtypes. From the case-case comparisons, we found that cases, who had consumed alcohol for more than 1 year were 3.4 times more likely to have ER+PR+ tumors than ER-PR- tumors (95% CI: 1.4-8.4).
Conclusions: Certain breast cancer risk factors may vary by ER and PR status, and joint ER/PR status should be taken into account in future studies of risk factor estimates.
Yaghjyan L, McLaughlin E, Lehman A, Neuhouser M, Rohan T, Lane D Eur J Nutr. 2022; 61(7):3449-3459.
PMID: 35583696 PMC: 10227860. DOI: 10.1007/s00394-022-02899-8.
Mammographic density parameters and breast cancer tumor characteristics among postmenopausal women.
Velasquez Garcia H, Gotay C, Wilson C, Lohrisch C, Lai A, Aronson K Breast Cancer (Dove Med Press). 2019; 11:261-271.
PMID: 31496793 PMC: 6702445. DOI: 10.2147/BCTT.S192766.
Tc-LHRH in tumor receptor imaging.
Hao D, Sun L, Hu X, Hao X Oncol Lett. 2017; 14(1):569-578.
PMID: 28693207 PMC: 5494691. DOI: 10.3892/ol.2017.6246.
Butler E, Tse C, Bell M, Conway K, Olshan A, Troester M Cancer Causes Control. 2016; 27(6):775-86.
PMID: 27153846 PMC: 5030064. DOI: 10.1007/s10552-016-0754-1.
Breastfeeding and breast cancer risk by receptor status--a systematic review and meta-analysis.
Islami F, Liu Y, Jemal A, Zhou J, Weiderpass E, Colditz G Ann Oncol. 2015; 26(12):2398-407.
PMID: 26504151 PMC: 4855244. DOI: 10.1093/annonc/mdv379.